The US District Court for the Eastern District of Pennsylvania holds that reverse payments cases will proceed to discovery in a patent litigation in the pharmaceutical sector (Cephalon)

In the latest development in the Federal Trade Commission’s efforts to challenge Hatch-Waxman patent litigation settlements, earlier this week a federal district court in Pennsylvania denied in part defendants’ motions to dismiss antitrust complaints challenging a series of such settlements. The court rejected the argument of the FTC and other plaintiffs that a settlement that includes a “reverse payment” from the patent holder to the generic entrant is a per se antitrust violation and adopted instead the “scope of the patent” standard followed by most other courts. Under that standard, the court concluded that plaintiffs had alleged sufficient facts that, if true, could establish that

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)
  • Covington & Burling (Washington)

Citation

Thomas O. Barnett, James R. Dean, Deborah A. Garza, John D. Graubert, Timothy C. Hester, James J. O'Connell, The US District Court for the Eastern District of Pennsylvania holds that reverse payments cases will proceed to discovery in a patent litigation in the pharmaceutical sector (Cephalon), 29 mars 2010, e-Competitions March 2010, Art. N° 95877

Visites 36

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues